Page 89 - 《中国药房》2025年10期
P. 89

综上所述,联用三联及以上抗菌药物、低血红蛋白                              ditions  through  biophysical  and  biochemical  means[J].
          水平、高血肌酐水平是吡拉西坦相关血小板减少症的独                                Blood,2024,144(14):1521-1531.
          立危险因素;所建风险预测模型具有良好的预测价值,                           [12]  XU D Z,HU X Y,ZHANG R J,et al. Effect of sunlight
          有助于临床识别吡拉西坦相关血小板减少症发生的潜                                 on vitamin D and hemoglobin levels among the residents
          在风险。                                                    of Ningbo,China[J]. Nutr Hosp,2024,41(4):850-857.
                                                             [13]  HANAI Y,MATSUO K,OGAWA M,et al. A retrospec‐
          参考文献
                                                                  tive study of the risk factors for linezolid-induced throm‐
          [ 1 ]  DONATO  H.  Neonatal  thrombocytopenia:a  review:Ⅰ :
                                                                  bocytopenia and anemia[J]. J Infect Chemother,2016,22
              definitions,differential diagnosis,causes,immune throm‐
                                                                 (8):536-542.
              bocytopenia[J]. Arch Argent Pediatr,2021,119(3):e202-
                                                             [14]  ABDULLAH  S  H,DYARY  H  O,SAEED  N  M.  Mole-
              e214.
                                                                  cular detection of Theileria spp. in native sheep and esti‐
          [ 2 ]  全军重症医学专业委员会,中华医学会检验医学分会 .
                                                                  mation of hemato-biochemical parameters from Sulaimani
              中国成人重症患者血小板减少诊疗专家共识[J]. 解放军
                                                                  province/Iraq[J]. Front Vet Sci,2022,9:1059599.
              医学杂志,2020,45(5):457-474.
                                                             [15]  BARKAT K,AHMAD M,MINHAS M U,et al. Develop‐
          [ 3 ]  刘翠丽,吴晨,王涛. 吡拉西坦制剂安全性风险分析及思
                                                                  ment of a simple chromatographic method for the determi‐
              考[J]. 中国药物警戒,2024,21(5):563-566.
                                                                  nation of piracetam in human plasma and its pharmacoki‐
          [ 4 ]  国家药品监督管理局. 国家药品监督管理局关于修订吡
                                                                  netic  evaluation[J].  Drug  Res(Stuttg),2014,64(7):
              拉西坦制剂说明书的公告:2023 年第 53 号[EB/OL].
                                                                  384-388.
              (2023-04-24)[2024-10-10]. https://www.nmpa.gov.cn/xxgk/
                                                             [16]  GOUHIE F A,BARBOSA K O,CRUZ A B R,et al. Cog‐
              ggtg/ypggtg/ypshmshxdgg/20230424170058104.html.
                                                                  nitive effects of piracetam in adults with memory impair‐
          [ 5 ]  王欣,刘琛,张艳红,等. 国内外药品不良反应报告质量
                                                                  ment:a systematic review and meta-analysis[J]. Clin Neu‐
              评价方法的研究进展[J]. 药物不良反应杂志,2023,25
                                                                  rol Neurosurg,2024,243:108358.
              (11):683-689.
                                                             [17]  ZHANG  D,XU  Y  S,WANG  X,et  al.  Risk  factors  for
          [ 6 ]  ALBA A C,AGORITSAS T,WALSH M,et al. Discrimi‐
                                                                  thrombocytopenia in patients receiving linezolid therapy:
              nation and calibration of clinical prediction models:users’
                                                                  a systematic review and meta-analysis[J]. Eur J Clin Phar‐
              guides to the medical literature[J]. JAMA,2017,318(14):
                                                                  macol,2023,79(10):1303-1314.
              1377-1384.
                                                             [18]  郭晓明,王莹,刘娜,等. 头孢哌酮钠舒巴坦钠致血小板
          [ 7 ]  周柳君,李晓玲,张青霞. 抗菌药物致老年人凝血功能异
                                                                  减少症的危险因素分析[J]. 中国医院用药评价与分析,
              常/血小板减少严重不良反应文献病例分析[J]. 实用药
                                                                  2021,21(10):1273-1276,1280.
              物与临床,2023,26(3):241-246.
                                                             [19]  GOULDEN  R,ROWE  B  H,ABRAHAMOWICZ  M,et
          [ 8 ]  宋景春,丁仁彧,吕奔,等 . 脓毒症性凝血病诊疗中国专
                                                                  al.  Association  of  intravenous  radiocontrast  with  kidney
              家共识:2024 版[J]. 解放军医学杂志,2024,49(11):
                                                                  function:a regression discontinuity analysis[J]. JAMA In‐
              1221-1236.
                                                                  tern Med,2021,181(6):767-774.
          [ 9 ]  蔡乐,汤智慧,邱子涵,等. 药源性血小板减少症的危险
                                                             [20]  EVERS S,GROTEMEYER K H. Piracetam and platelets:
              因素分析与风险预测模型的构建[J]. 临床药物治疗杂
                                                                  a review of laboratory and clinical data[J]. Pharmacopsy‐
              志,2024,22(8):22-28.
                                                                  chiatry,1999,32(Suppl. 1):44-48.
          [10]  王萧,贺艳,邬闻文,等 . 肺部感染患者美罗培南相关血
                                                             [21]  DEEREN  D,DELEU  L.  Piracetam-induced  immune
              小板减少症的影响因素分析[J]. 中国医院药学杂志,
                                                                  thrombocytopenia[J]. Epileptic Disord,2011,13(2):226.
              2024,44(5):564-569.
                                                                            (收稿日期:2024-10-31  修回日期:2025-03-19)
          [11]  JIANG D,HOUCK K L,MURDIYARSO L,et al. RBCs
                                                                                                  (编辑:张元媛)
              regulate platelet function and hemostasis under shear con‐










          中国药房  2025年第36卷第10期                                              China Pharmacy  2025 Vol. 36  No. 10    · 1231 ·
   84   85   86   87   88   89   90   91   92   93   94